Danielle Antalffy
Stock Analyst at UBS
(3.42)
# 939
Out of 4,650 analysts
173
Total ratings
48.21%
Success rate
3.69%
Average return
Main Sectors:
Stocks Rated by Danielle Antalffy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABT Abbott Laboratories | Maintains: Buy | $143 → $146 | $114.07 | +27.99% | 11 | Oct 17, 2024 | |
| EW Edwards Lifesciences | Maintains: Neutral | $90 → $75 | $68.52 | +9.46% | 12 | Sep 10, 2024 | |
| MDT Medtronic | Upgrades: Neutral | $76 → $90 | $90.60 | -0.66% | 7 | Aug 15, 2024 | |
| ZBH Zimmer Biomet Holdings | Maintains: Sell | $112 → $107 | $103.60 | +3.28% | 4 | Aug 8, 2024 | |
| TMCI Treace Medical Concepts | Maintains: Neutral | $6.5 → $7 | $4.84 | +44.63% | 5 | Aug 7, 2024 | |
| SYK Stryker | Maintains: Neutral | $351 → $366 | $356.01 | +2.81% | 5 | Jul 31, 2024 | |
| DXCM DexCom | Maintains: Buy | $163 → $95 | $72.10 | +31.76% | 8 | Jul 26, 2024 | |
| BSX Boston Scientific | Maintains: Buy | $74 → $90 | $84.76 | +6.18% | 11 | Apr 25, 2024 | |
| ATRC AtriCure | Maintains: Buy | $57 → $58 | $28.75 | +101.74% | 11 | Feb 16, 2024 | |
| INMD InMode | Maintains: Neutral | $24 → $26 | $17.98 | +44.61% | 3 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $41.17 | +82.17% | 1 | Jan 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $180 | $161.60 | +11.39% | 4 | Dec 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $405 → $322 | $194.68 | +65.40% | 5 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $2.25 | $1.89 | +19.05% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $43 | $36.01 | +19.41% | 5 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $278 | $510.88 | -45.58% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $45 | $32.75 | +37.40% | 14 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $50.25 | -72.14% | 1 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $300 → $280 | $233.37 | +19.98% | 12 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $55 | $0.55 | +9,831.38% | 2 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $14 | $13.94 | +0.43% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $100 | $110.10 | -9.17% | 2 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $12 | $6.38 | +88.09% | 3 | Mar 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $30 | $91.00 | -67.03% | 3 | Mar 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $65 | $70.24 | -7.46% | 6 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $45.66 | -1.45% | 4 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $105 → $85 | $4.91 | +1,631.16% | 10 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $95 | $42.56 | +123.21% | 6 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $270 → $275 | $238.91 | +15.11% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $20 | $2.95 | +577.97% | 3 | Nov 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $72 → $42 | $9.29 | +352.34% | 7 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $3 | $0.34 | +770.07% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $1.01 | +1,385.15% | 1 | Sep 1, 2020 |
Abbott Laboratories
Oct 17, 2024
Maintains: Buy
Price Target: $143 → $146
Current: $114.07
Upside: +27.99%
Edwards Lifesciences
Sep 10, 2024
Maintains: Neutral
Price Target: $90 → $75
Current: $68.52
Upside: +9.46%
Medtronic
Aug 15, 2024
Upgrades: Neutral
Price Target: $76 → $90
Current: $90.60
Upside: -0.66%
Zimmer Biomet Holdings
Aug 8, 2024
Maintains: Sell
Price Target: $112 → $107
Current: $103.60
Upside: +3.28%
Treace Medical Concepts
Aug 7, 2024
Maintains: Neutral
Price Target: $6.5 → $7
Current: $4.84
Upside: +44.63%
Stryker
Jul 31, 2024
Maintains: Neutral
Price Target: $351 → $366
Current: $356.01
Upside: +2.81%
DexCom
Jul 26, 2024
Maintains: Buy
Price Target: $163 → $95
Current: $72.10
Upside: +31.76%
Boston Scientific
Apr 25, 2024
Maintains: Buy
Price Target: $74 → $90
Current: $84.76
Upside: +6.18%
AtriCure
Feb 16, 2024
Maintains: Buy
Price Target: $57 → $58
Current: $28.75
Upside: +101.74%
InMode
Feb 14, 2024
Maintains: Neutral
Price Target: $24 → $26
Current: $17.98
Upside: +44.61%
Jan 22, 2024
Initiates: Buy
Price Target: $75
Current: $41.17
Upside: +82.17%
Dec 1, 2023
Upgrades: Buy
Price Target: $180
Current: $161.60
Upside: +11.39%
Sep 6, 2023
Maintains: Buy
Price Target: $405 → $322
Current: $194.68
Upside: +65.40%
Mar 29, 2023
Initiates: Neutral
Price Target: $2.25
Current: $1.89
Upside: +19.05%
Mar 29, 2023
Initiates: Neutral
Price Target: $43
Current: $36.01
Upside: +19.41%
Mar 29, 2023
Initiates: Neutral
Price Target: $278
Current: $510.88
Upside: -45.58%
Mar 29, 2023
Initiates: Neutral
Price Target: $45
Current: $32.75
Upside: +37.40%
May 6, 2022
Maintains: Outperform
Price Target: $16 → $14
Current: $50.25
Upside: -72.14%
May 6, 2022
Maintains: Outperform
Price Target: $300 → $280
Current: $233.37
Upside: +19.98%
May 5, 2022
Maintains: Outperform
Price Target: $65 → $55
Current: $0.55
Upside: +9,831.38%
May 5, 2022
Maintains: Outperform
Price Target: $12 → $14
Current: $13.94
Upside: +0.43%
May 2, 2022
Maintains: Outperform
Price Target: $75 → $100
Current: $110.10
Upside: -9.17%
Mar 11, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $6.38
Upside: +88.09%
Mar 9, 2022
Maintains: Outperform
Price Target: $25 → $30
Current: $91.00
Upside: -67.03%
Feb 25, 2022
Maintains: Outperform
Price Target: $60 → $65
Current: $70.24
Upside: -7.46%
Feb 25, 2022
Maintains: Outperform
Price Target: $40 → $45
Current: $45.66
Upside: -1.45%
Feb 24, 2022
Maintains: Outperform
Price Target: $105 → $85
Current: $4.91
Upside: +1,631.16%
Feb 24, 2022
Maintains: Outperform
Price Target: $85 → $95
Current: $42.56
Upside: +123.21%
Feb 4, 2022
Maintains: Market Perform
Price Target: $270 → $275
Current: $238.91
Upside: +15.11%
Nov 10, 2021
Maintains: Outperform
Price Target: $26 → $20
Current: $2.95
Upside: +577.97%
Nov 5, 2021
Maintains: Market Perform
Price Target: $72 → $42
Current: $9.29
Upside: +352.34%
Apr 1, 2021
Downgrades: Market Perform
Price Target: $3
Current: $0.34
Upside: +770.07%
Sep 1, 2020
Initiates: Outperform
Price Target: $15
Current: $1.01
Upside: +1,385.15%